Updated Analysis of Overall Survival With Imetelstat in Relapsed or Refractory Myelofibrosis From IMbark Versus Real-World Data and Assessment of Real-World Treatment Patterns: Updated Post Hoc Analysis With Extended Follow-Up (SOHO 2026) - Sep 1, 2026 - Abstract #MPN-269; Location: LEVEL 3, HALL B3; P2 | "RW treatment patterns, baseline/disease characteristics, and mOS of patients diagnosed before/after 2016 (cut point selected to match diagnosis period of IMbark population) and 2019 (fedratinib US approval) were compared. A more favorable OS benefit with imetelstat versus BAT in RW patients with R/R myelofibrosis and poor prognosis was observed. The significant improvement in OS in RW patients over the last decade was independent of transplant status, potentially due to shorter time from diagnosis to ruxolitinib start and earlier switch to next-line JAKi or clinical trial. Evolving treatment patterns are key considerations for interpreting future clinical trial outcomes."
Clinical • HEOR • Real-world • Real-world evidence • Retrospective data • Myelofibrosis • Oncology
|
|
Andrew T Kuykendall MD 1; Hana Qasim MBBS 1; Ghada Araji MD 1; Libo Sun PhD 2; Qi Xia PhD 2; Michelle Mudge-Riley DOMHARDN 2; Joseph Eid MD 2; Rami S Komrokji MD 1
|